Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Location status: Recruiting
NCT Number: NCT05759143
This research is being done to develop the electronic platform Nest for young adults (ages 18-39) who have had prior cancer genetic testing. The platform will give patients and their clinicians access to continuously updated information about both pathogenic variants and variants of uncertain significance (VUS).
The name of the intervention used in this research study is:
Nest portal (electronic platform for patients and clinicians)
Interested in participating?
Request Info18 year–39 year
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02115, United States
Location status: Recruiting
The goal of the electronic platform Nest is to help patients understand and manage genetic test results and recommended care and to help clinicians with access to results and recommendations, facilitating orders, and documentation. The portal has two parts, one for participants and one for clinicians.
For the first phase of the study, participants will give their feedback on the Nest portal's content and processes that will guide refinement of the portal. The Pilot phase will test the feasibility and acceptability of the intervention.
The research study procedures include a baseline survey, using the portal after receiving a brief orientation from the study team, a follow-up survey, and then a 30-minute interview.
Participants will be in this research study for up to 2 hours.
It is expected that about 40 people will take part in this research study.
The electronic platform is being developed by Nest Genomics.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
AIM 1:
Inclusion criteria
AIM 2:
Patient- and clinician-facing portal via secure link
Time frame: 2 hours
Defined as > 70% of consenting participants who use the intervention.
Time frame: 2 hours
Defined as > 70% of consenting clinicians who use the intervention.
Time frame: At post-visit survey, up to 2 hours
Defined as >70% of clinicians consider the intervention feasible as assessed by the post-visit survey.
Time frame: At post-visit survey, up to 30 days
Defined as > 70% of young adult participants consider the intervention successful as measured by a post-visit AIM score >4
Time frame: at post-visit survey, up to 2 hours
Defined as > 70% of clinicians consider the intervention successful as measured by a post-visit AIM score >4
Time frame: Baseline and post visit up to 2 hours
Change in cancer knowledge will be assessed by participant survey at baseline and post visit.
Time frame: Baseline and post visit up to 2 hours
Change in Recommended screening will be assessed by participant survey at baseline and post visit.
Contact information is provided by the study sponsor or research team.
Dana-Farber Cancer Institute
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07018128
Breathing, Mouth, Disease Attributes
MueangChonburi, Changwat Chon Buri, Thailand
View Trial DetailsNCT07112287
Disease Attributes, Disease Susceptibility
Boston, Massachusetts, United States
View Trial DetailsNCT06057181
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes
Fort Wayne, Indiana, United States
View Trial DetailsNCT05020574
Breast Cancer, Breast Cancer Female
San Francisco, California, United States
View Trial Details